PureIMS

Executive Summary

PureIMS is a Netherlands-based digital health company specializing in respiratory drug delivery. Its flagship product, Cyclops®, is a state-of-the-art, easy-to-use pre-filled dry powder inhaler (DPI) designed for efficient inhalation powder delivery. The device leverages a simple yet sophisticated proprietary design, aiming to enhance patient adherence and therapeutic outcomes. Founded in 2017 and operating from Amsterdam, PureIMS is well-positioned in the growing digital health and AI-driven personalized medicine space. The company is privately held, with no disclosed funding or valuation, and is at an early stage of commercialization. PureIMS focuses on addressing unmet needs in respiratory care by offering a device that can be integrated with digital monitoring and data analytics to optimize treatment. With the global DPI market expanding due to the rise in asthma and COPD prevalence, PureIMS has the potential to capture significant value if it secures regulatory approvals and strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026CE Mark Approval for Cyclops DPI60% success
• Q4 2026Licensing Deal with Major Pharma35% success
• Q2 2026Publication of Clinical Usability Study Results70% success